Kodiak Sciences Inc. (KOD) stock analysis
In our weekly check, Kodiak Sciences Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 9.
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KOD.
What our checks show for KOD
Red flags
- Weak EPS forecast
- Earnings per share fell 13.9% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 104% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 96% from a peak. Would you have held through that?
- Beta 2.04: the stock usually moves more than the market, both up and down.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Recovering from its deepest fall took about 2.3 years.
Strengths
- Debt is low: 3.7x equity.
- Analysts expect the net margin to improve by 12 points from today's 0%.
Similar companies
TXG · IMVT · ORKA · ARWR · TWST · CGON
Questions
What grade does Kodiak Sciences Inc. (KOD) have?
In our weekly check, Kodiak Sciences Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 9. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of KOD stock?
This week's biggest flags for Kodiak Sciences Inc.: Weak EPS forecast, Weak EPS growth, Thin margins. In total 11 of 18 checks show a warning or a red flag.
What does Kodiak Sciences Inc. do?
Kodiak Sciences Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KOD.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis